<DOC>
	<DOC>NCT01139723</DOC>
	<brief_summary>This is a Phase I, first-in-human, open label, dose-escalation study of MINT1526A administered alone and in combination with bevacizumab by IV infusion every 3 weeks to patients with advanced solid tumors for whom standard therapy either does not exist or has proven to be ineffective or intolerable.</brief_summary>
	<brief_title>A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically or cytologically documented, incurable, or metastatic solid malignancy that has progressed on or failed to respond to regimens or therapies known to provide clinical benefit Adequate hematologic and end organ function Evaluable disease or measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.0; prostate cancer patients with nonevaluable or nonmeasurable disease if they have an increase in prostatespecific antigen (PSA); ovarian cancer patients with nonevaluable or nonmeasurable disease if they have an increase in cancer antigen 125 (CA125) For female patients of childbearing potential and male patients with partners of childbearing potential, agreement to use an effective form of contraception and to continue its use for 6 months after discontinuation from the study Any anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy within a specified timeframe prior to initiation of study treatment. Leptomeningeal disease Active infection requiring intravenous antibiotics Active autoimmune disease that is not controlled by nonsteroidal antiinflammatory drugs, inhaled corticosteroids, or prednisone Bisphosphonate therapy for symptomatic hypercalcemia Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, or cirrhosis Known primary central nervous system (CNS) malignancy or untreated or active CNS metastases Pregnancy, lactation, or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>